|
| 35985457 | The Fraction Size Sensitivity of Late Genitourinary Toxicity: Analysis of Alpha/Beta (α/β) Ratios in the CHHiP Trial. | Int J Radiat Oncol Biol Phys | 2023 |
| 37348521 | Independent SARS-CoV-2 staff testing protected academic and health-care institutions in northwest London. | Lancet | 2023 |
| 37116490 | Sotrovimab restores neutralization against current Omicron subvariants in patients with blood cancer. | Cancer Cell | 2023 |
| 37433374 | Gastrointestinal Toxicity Prediction Not Influenced by Rectal Contour or Dose-Volume Histogram Definition. | Int J Radiat Oncol Biol Phys | 2023 |
| 36805131 | Patterns of Failure After Stereotactic Body Radiotherapy to Sacral Metastases. | Clin Oncol (R Coll Radiol) | 2023 |
| 36831631 | The Association between Acute and Late Genitourinary and Gastrointestinal Toxicities: An Analysis of the PACE B Study. | Cancers (Basel) | 2023 |
| 36634852 | Interobserver variation in clinical target volume (CTV) delineation for stereotactic radiotherapy to non-spinal bone metastases in prostate cancer: CT, MRI and PET/CT fusion. | Radiother Oncol | 2023 |
| 34756755 | Metastasis-directed Therapy in Prostate Cancer: Prognostic Significance of the ESTRO/EORTC Classification in Oligometastatic Bone Disease. | Clin Oncol (R Coll Radiol) | 2022 |
| 35469741 | Prostate Volume Changes during Extreme and Moderately Hypofractionated Magnetic Resonance Image-guided Radiotherapy. | Clin Oncol (R Coll Radiol) | 2022 |
| 35656509 | Oligoprogression in Metastatic, Castrate-Resistant Prostate Cancer-Prevalence and Current Clinical Practice. | Front Oncol | 2022 |
| 35413273 | Immune responses following third COVID-19 vaccination are reduced in patients with hematological malignancies compared to patients with solid cancer. | Cancer Cell | 2022 |
| 36240755 | Functional immune responses against SARS-CoV-2 variants of concern after fourth COVID-19 vaccine dose or infection in patients with blood cancer. | Cell Rep Med | 2022 |
| 36113498 | Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial. | Lancet Oncol | 2022 |
| 35227544 | Stereotactic Ablative Radiotherapy for Oligometastatic Disease: A Tale of Emperor's New Clothes or New Standard of Care? | Clin Oncol (R Coll Radiol) | 2022 |
| 35093250 | In Reply to Onal et al. | Clin Oncol (R Coll Radiol) | 2022 |
| 35090602 | Omicron neutralising antibodies after third COVID-19 vaccine dose in patients with cancer. | Lancet | 2022 |
| 35272913 | UK 2022 Consensus on Normal Tissue Dose-Volume Constraints for Oligometastatic, Primary Lung and Hepatocellular Carcinoma Stereotactic Ablative Radiotherapy. | Clin Oncol (R Coll Radiol) | 2022 |
| 33412260 | Estimates of Alpha/Beta (α/β) Ratios for Individual Late Rectal Toxicity Endpoints: An Analysis of the CHHiP Trial. | Int J Radiat Oncol Biol Phys | 2021 |
| 33883723 | Single dose prostate radiotherapy - a step too far? | Nat Rev Urol | 2021 |
| 33794211 | Stereotactic radiotherapy and oligometastases - Authors' reply. | Lancet Oncol | 2021 |
| 34950880 | Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: The CAPTURE study. | Nat Cancer | 2021 |
| 35121899 | Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study. | Nat Cancer | 2021 |
| 35121900 | Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study. | Nat Cancer | 2021 |
| 34580668 | Functional antibody and T-cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study. | Res Sq | 2021 |
| 33965893 | Salvage stereotactic body radiotherapy (SBRT) for intraprostatic relapse after prostate cancer radiotherapy: An ESTRO ACROP Delphi consensus. | Cancer Treat Rev | 2021 |
| 33387498 | Stereotactic ablative body radiotherapy in patients with oligometastatic cancers: a prospective, registry-based, single-arm, observational, evaluation study. | Lancet Oncol | 2021 |
| 32423621 | Clinical Outcomes of Stereotactic Body Radiotherapy With Immediate Versus Delayed Hormone Therapy in Men With Oligometastatic Recurrence of Prostate Cancer. | Clin Oncol (R Coll Radiol) | 2020 |
| 32068113 | Effect of <sup>18</sup>F-Fluciclovine Positron Emission Tomography on the Management of Patients With Recurrence of Prostate Cancer: Results From the FALCON Trial. | Int J Radiat Oncol Biol Phys | 2020 |
| 33145444 | Stereotactic radiotherapy with focal boost for intermediate and high-risk prostate cancer: Initial results of the SPARC trial. | Clin Transl Radiat Oncol | 2020 |
| 32840422 | Squamous Non-Small-Cell Lung Cancer Molecularly Reclassified as Transdifferentiated Prostate Cancer Due to Identification of <i>TMPRSS2-ERG</i> Translocation With <i>SOX2</i> Amplification. | JCO Oncol Pract | 2020 |
| 30676772 | Comparison of prostate delineation on multimodality imaging for MR-guided radiotherapy. | Br J Radiol | 2019 |
| 31797788 | Optimal patient selection for stereotactic body radiotherapy - Authors' reply. | Lancet Oncol | 2019 |
| 31346760 | Stereotactic body radiotherapy for bone oligometastatic disease in prostate cancer. | World J Urol | 2019 |
| 31540791 | Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial. | Lancet Oncol | 2019 |
| 31563410 | Patterns of recurrence after prostate bed radiotherapy. | Radiother Oncol | 2019 |
| 31331782 | Metastasis-directed Therapy in Treating Nodal Oligorecurrent Prostate Cancer: A Multi-institutional Analysis Comparing the Outcome and Toxicity of Stereotactic Body Radiotherapy and Elective Nodal Radiotherapy. | Eur Urol | 2019 |
| 30919165 | Trends in Management of Oligometastatic Hormone-Sensitive Prostate Cancer. | Curr Oncol Rep | 2019 |
| 30756456 | Improving fiducial and prostate capsule visualization for radiotherapy planning using MRI. | J Appl Clin Med Phys | 2019 |
| 29033164 | UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy. | Clin Oncol (R Coll Radiol) | 2018 |
| 29807801 | An Investigation of Dosimetric Correlates of Acute Toxicity in Prostate Stereotactic Body Radiotherapy: Dose to Urinary Trigone is Associated with Acute Urinary Toxicity. | Clin Oncol (R Coll Radiol) | 2018 |
| 30064301 | Stereotactic Body Radiotherapy for Primary Prostate Cancer. | Technol Cancer Res Treat | 2018 |
| 29362999 | Abstracts of the 33rd International Austrian Winter Symposium : Zell am See, Austria. 24-27 January 2018. | EJNMMI Res | 2018 |
| 29353654 | Magnetic Resonance Imaging-Guided Adaptive Radiation Therapy: A "Game Changer" for Prostate Treatment? | Int J Radiat Oncol Biol Phys | 2018 |
| 29662167 | Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets. | Nat Genet | 2018 |
| 29621134 | Dosimetric Implications of Computerised Tomography-Only versus Magnetic Resonance-Fusion Contouring in Stereotactic Body Radiotherapy for Prostate Cancer. | Medicines (Basel) | 2018 |
| 27560549 | Association of Survival Benefit With Docetaxel in Prostate Cancer and Total Number of Cycles Administered: A Post Hoc Analysis of the Mainsail Study. | JAMA Oncol | 2017 |
| 28939224 | Phase 1/2 Dose-Escalation Study of the Use of Intensity Modulated Radiation Therapy to Treat the Prostate and Pelvic Nodes in Patients With Prostate Cancer. | Int J Radiat Oncol Biol Phys | 2017 |
| 28652092 | Upfront Docetaxel in the Post-STAMPEDE World: Lessons from an Early Evaluation of Non-trial Usage in Hormone-Sensitive Prostate Cancer. | Clin Oncol (R Coll Radiol) | 2017 |
| 28571827 | Effect on Overall Survival of Locoregional Treatment in a Cohort of De Novo Metastatic Prostate Cancer Patients: A Single Institution Retrospective Analysis From the Royal Marsden Hospital. | Clin Genitourin Cancer | 2017 |
| 28679552 | Randomized controlled trial of dietary fiber for the prevention of radiation-induced gastrointestinal toxicity during pelvic radiotherapy. | Am J Clin Nutr | 2017 |